Healthy Skepticism Library item: 12633
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
Won TesorIiero H.
Trouble Brews Over Merck Product
The Wall Street Journal 2008 Jan 30
http://online.wsj.com/article/SB120165519331327133.html?mod=googlenews_wsj
Abstract:
Merck & Co.‘s pending $4.85 billion Vioxx settlement is expected to bring more than three years of litigation to an end. But looming challenges to some top-selling products, including osteoporosis blockbuster Fosamax, threaten to keep the company under a cloud.
The headline headache of late has been Vytorin. For months, critics have assailed how Merck and Schering-Plough Corp. handled disappointing trial results for their anticholesterol drug. A congressional probe has yet to reach full speed, and New York and Connecticut officials have disclosed investigations. Investors will be looking for an update as Merck reports earnings today.
The company’s Gardasil cervical-cancer …
